ClinicalTrials.gg
RecruitingNCT07240610AURICREUpdated Dec 5, 2025

Abscopal Effect of Ultra-Hypofractionated Radiation Plus Immunotherapy in Metastatic Renal Cell Carcinoma

An observational study in Renal Cell Cancer Metastatic, sponsored by Zhe Chen. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Zhe Chen · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
145
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Carcinoma, Renal Cell with a site in Japan — 6 open to participants now, 17 under way, 6 of them phase 3. Carcinoma, Renal Cell · Japan.

Planned enrollment
8th of 11
145 · median 286
Started
2025
with 1 other
Observational
11 of 71
1 open now
Primary completion
2028-03
later than 13 of 16 live
Registered
70th of 71
by date

Among the 71 studies in Carcinoma, Renal Cell with a site in Japan, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2025, is one of 11 observational ones, reaches primary completion later than 13 of the 16 other live ones, and was the 70th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

6 of the 71 studies in Carcinoma, Renal Cell with a site in Japan are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Carcinoma, Renal Cell with a site in Japan, or all of them as a file.
02

Study summary

The goal of this multicenter observational study is to elucidate the clinical and immunological characteristics of the abscopal effect in patients with metastatic renal cell carcinoma (mRCC) receiving immune checkpoint inhibitors (ICI) combined with image-guided ultra-hypofractionated radiotherapy (IGU).

The main questions this study aims to answer are:

What is the abscopal response rate (ARR) at one year after IGU in patients continuing ICI treatment?

What clinical and immunological factors are associated with the occurrence and timing of the abscopal effect?

Participants are patients with mRCC who have experienced immune-confirmed stable or progressive disease during ICI therapy and are scheduled to receive IGU to a selected lesion. Researchers will observe tumor responses at irradiated and non-irradiated sites using standard imaging (CT/MRI) and collect clinical and laboratory data at baseline, 3, 6, 9, and 12 months after IGU. Optional exploratory blood samples will be obtained for cytokine analysis (e.g., IFN-β, IFN-γ, TNF-α, IL-6).

The primary outcome is the abscopal response rate (ARR) at one year after IGU. Secondary outcomes include tumor shrinkage rate of irradiated and non-irradiated lesions, 1-year overall survival, disease-specific survival, and progression-free survival.

This study seeks to establish a foundation for developing combined immunotherapy and ultra-hypofractionated radiotherapy strategies for metastatic renal cell carcinoma.

*This study is led by Prof. Hiroshi Onishi (University of Yamanashi). The registry entry is managed by Dr. Zhe Chen on behalf of the study group.

Read the detailed description

Renal cell carcinoma (RCC) is a highly immunogenic tumor that exhibits intrinsic resistance to cytotoxic chemotherapy and conventional radiotherapy. With the introduction of immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, the survival outcomes of patients with metastatic RCC (mRCC) have markedly improved. However, disease control remains suboptimal in a considerable fraction of patients who experience immune-confirmed stable disease or progression despite continued ICI therapy. For such patients, locoregional treatment targeting oligoprogressive lesions may modulate tumor immunogenicity and enhance systemic immune responses.

Radiation therapy, particularly when administered in large doses per fraction (ablative or ultra-hypofractionated schedules), can induce systemic antitumor effects mediated by immune activation, known as the abscopal effect. This effect refers to regression of non-irradiated metastatic lesions following local irradiation, thought to arise from radiation-induced antigen release and subsequent immune activation. Although multiple case reports and small series have described this phenomenon, the true frequency, biological basis, and predictive factors of the abscopal effect in mRCC remain poorly defined.

The AURICRE study (Observational Study on the Abscopal Effect by Ultra-Hypofractionated Radiation Therapy in Combination with Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma) is a multicenter prospective observational registry initiated by the Department of Imaging-Integrative Therapeutic Radiology, University of Yamanashi. The study is designed to clarify the incidence, timing, and clinical-immunological correlates of the abscopal effect in patients with mRCC treated with ICIs who undergo ultra-hypofractionated image-guided radiotherapy (IGU) to a metastatic lesion. This investigation will also provide a foundation for the rational development of future ICI-radiotherapy combination strategies.

Study Objectives

Primary Objective To elucidate the clinical and immunological characteristics associated with the abscopal effect in mRCC patients receiving ICIs and to determine the abscopal response rate (ARR) at one year after IGU.

Secondary Objectives

To evaluate:

The tumor shrinkage rate of irradiated and non-irradiated lesions at each follow-up interval

One-year overall survival (OS)

One-year disease-specific survival (DSS)

One-year progression-free survival (PFS)

Exploratory Objectives To explore cytokine dynamics and immune biomarkers (e.g., IFN-β, IFN-γ, TNF-α, IL-6) that may predict or accompany the abscopal effect.

Study Design

This study is a prospective, multicenter, observational design conducted from 2025 to 2028. Eligible patients are adults with histologically confirmed metastatic RCC who have received ICIs and demonstrated immune-confirmed stable disease or progression. Participants must be candidates for ultra-hypofractionated radiotherapy to at least one metastatic lesion according to clinical judgment. There is no randomization or additional therapeutic intervention mandated by the protocol beyond standard care.

Treatment and Assessment Schedule

IGU will be performed using stereotactic or equivalent ultra-hypofractionated techniques (typically 24-30 Gy in 1-3 fractions) targeting a single or limited number of lesions, with attention to organ-at-risk constraints. The selection of the irradiation site and dose prescription will follow institutional standards.

Participants will continue ICI therapy at the discretion of their treating oncologist. Imaging assessments (CT or MRI) will be performed at baseline, and at 3, 6, 9, and 12 months post-IGU to evaluate responses in irradiated and non-irradiated lesions based on RECIST 1.1 criteria and radiological review. Optional exploratory blood sampling for cytokine analysis will be performed at corresponding time points. Clinical status, laboratory parameters, and toxicity will be documented throughout the observation period.

Endpoints and Data Collection

Primary Endpoint

Abscopal response rate (ARR) at one year after IGU, defined as a ≥30 % reduction in the sum of diameters of non-irradiated target lesions without new lesion appearance.

Secondary Endpoints

Tumor shrinkage rates of irradiated and non-irradiated lesions

1-year OS, DSS, and PFS

Patterns and timing of the abscopal response

Exploratory Endpoints

Temporal changes in serum cytokine levels

Correlation between immune parameters and clinical response

Data will be collected using an electronic data capture (EDC) system. Each participating site will record baseline demographics, disease characteristics, treatment details, and follow-up results in standardized formats to ensure uniformity across institutions.

Sample Size and Statistical Considerations

The target accrual is approximately 50-60 patients based on feasibility across participating centers. Statistical analyses will include logistic regression to assess predictors of the abscopal response, incorporating variables such as age, sex, number of lesions, prior lines of therapy, and ICI type. Receiver operating characteristic (ROC) curve analysis will determine optimal cut-off values for significant predictors. Survival outcomes will be estimated using the Kaplan-Meier method. Missing data will be analyzed for pattern and mechanism; if imputation is warranted, multiple imputation or appropriate statistical techniques will be employed.

Ethical Considerations and Oversight

This study is conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Japan). The protocol and informed consent documents have been approved by the University of Yamanashi Ethics Committee (approval date: October 27, 2025). Each participating institution will obtain local approval where required. Written informed consent will be obtained from all participants prior to enrollment.

Scientific and Clinical Significance

The AURICRE study will be among the first systematic multicenter efforts to characterize the abscopal effect in mRCC under contemporary immunotherapy settings. By integrating clinical outcomes, radiologic responses, and exploratory immune profiling, this study will clarify real-world frequency and predictors of systemic immune activation triggered by ultra-hypofractionated radiotherapy. The findings are expected to provide a mechanistic and clinical rationale for future prospective trials combining radiotherapy and immunotherapy, ultimately contributing to the advancement of immune-radiotherapeutic strategies for renal cell carcinoma.

03

Conditions studied

  • Renal Cell Cancer Metastatic

Keywords

  • Abscopal Effect
  • Ultra-Hypofractionated Radiotherapy
  • Immune Checkpoint Inhibitors
  • Metastatic Renal Cell Carcinoma
  • Immunoradiotherapy Combination
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (≥18 years) with histologically confirmed metastatic renal cell carcinoma (mRCC) who are receiving ICIs and are candidates for IGU to one or more metastatic lesions. Eligible patients must have immune-confirmed stable disease or progression during ongoing ICI therapy. Enrollment will include patients treated at participating centers of the AURICRE multicenter registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged 18 years and above with renal cell carcinoma
  2. Patients currently receiving (ICI) therapy who are assessed as having iCPD or iSD according to
  3. Presence of two or more clinically (assessed by CT, MRI, physical examination, or visual inspection) Note: Osteosclerotic lesions without measurable soft-tissue components are excluded
  4. Planned to undergo IGU to the target lesion
  5. Provided written after receiving sufficient explanation of this study Note: Proxy signature is permitted if the patient is physically unable to sign

Exclusion criteria

Exclusion Criteria:

  1. Patients with active double cancers (synchronous double cancers or metachronous double cancers with a disease-free interval within 2 years).

    However, carcinoma in situ or intramucosal carcinoma considered cured by treatment, and the following tumors even if within 2 years of disease-free interval are not excluded: gastric cancer stage 0-II (UICC), prostate cancer stage I-III, colorectal cancer stage 0-II, esophageal cancer stage 0-I, breast cancer stage 0-II, endometrial cancer stage I-II, cervical cancer stage 0-II, and thyroid cancer stage I-III. In addition, any cancer with a disease-free interval greater than 2 years is not excluded regardless of stage.

  2. Patients with serious comorbidities, such as:

    • severe cardiac disease
    • uncontrolled diabetes mellitus despite continuous insulin therapy
    • myocardial infarction within 6 months
    • uncontrolled hypertension
    • active infections (bacterial, viral, or fungal)
    • diarrhea (watery stool), paralytic ileus, or bowel obstruction
    • disease
    • any other severe comorbid condition
  3. Patients with clear evidence of idiopathic interstitial pneumonia (usual interstitial pneumonia pattern) on chest X-ray or CT
  4. Patients with acute-phase pneumonia
  5. Patients with psychiatric disorders or psychiatric symptoms judged to make study participation difficult
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
145 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • mRCC patients receiving ICIs and IGU

    This cohort includes patients with histologically confirmed mRCC who are receiving ICIs and undergo IGU to a selected metastatic lesion as part of their standard clinical care. Patients are followed prospectively for one year to evaluate abscopal responses, survival outcomes, and immune-related biomarkers.

06

What researchers measure

Primary outcomes

  1. Abscopal Response Rate (ARR) at 1 Year After IGU

    The proportion of patients showing an abscopal response, defined as a ≥30% reduction in the sum of diameters of non-irradiated target lesions without new lesion appearance, evaluated according to RECIST 1.1 criteria. Tumor response will be assessed by radiological imaging (CT or MRI) at each follow-up visit and confirmed by central review.

    Time frame: 12 months after image-guided ultra-hypofractionated radiotherapy (IGU)

Secondary outcomes

  1. Tumor Shrinkage Rate of Irradiated and Non-Irradiated Lesions

    The percentage change in the sum of diameters of irradiated and non-irradiated lesions from baseline, assessed by RECIST 1.1 at each follow-up (3, 6, 9, and 12 months).

    Time frame: Baseline to 12 months after IGU

  2. One-Year Overall Survival (OS)

    Overall survival defined as the time from initiation of IGU to death from any cause. Patients alive at the end of follow-up will be censored at the date of last contact.

    Time frame: 12 months after IGU

  3. One-Year Disease-Specific Survival (DSS)

    Disease-specific survival defined as the time from IGU to death due to renal cell carcinoma. Deaths from other causes will be censored at the date of death.

    Time frame: 12 months after IGU

  4. One-Year Progression-Free Survival (PFS)

    Progression-free survival defined as the time from IGU to disease progression or death, whichever occurs first, based on RECIST 1.1 criteria.

    Time frame: 12 months after IGU

Other outcomes

  1. Temporal Changes and Correlation of Serum Cytokine Profiles With Abscopal Response

    Quantitative changes in circulating cytokines (IFN-β, IFN-γ, TNF-α, IL-6) measured by enzyme-linked immunosorbent assay (ELISA) at baseline and 3 and 12 months after IGU. Statistical correlations between cytokine dynamics and abscopal response rate will be analyzed using logistic regression and receiver operating characteristic (ROC) analysis.

    Time frame: Baseline to 12 months after IGU

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chen Z, Onishi H, Mitsui T, Nakao A, Yokomichi H, Tsukahara M, Mochizuki S, Marino K, Komiyama T. Abscopal responses following stereotactic ablative radiotherapy during immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: protocol for the prospective multicentre observational AURICRE study in Japan. BMJ Open. 2026 Jul 7;16(7):e118228. doi: 10.1136/bmjopen-2026-118228. PubMed 42414009 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because the study involves identifiable clinical information collected in a multicenter observational registry. Data sharing is restricted by institutional and ethical regulations at participating sites, and access is limited to the study investigators for predefined analyses.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2028, 28 months after the start.

Of 97 non-industry observational studies under Carcinoma, Renal Cell, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 241. This study's planned 28 months is below that.

Counting every sponsor, half of 139 studies reached it within 50 months; a quarter within 33 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 21, 2025
StartActual
Nov 10, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Sep 30, 2029
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07240610
Lead sponsor
Zhe Chen
Collaborators
Participating institutions of the AURICRE Study Group
Responsible party
Zhe Chen (Lecturer, University of Yamanashi) — Sponsor-investigator
First posted
Nov 21, 2025
Start date
Nov 10, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Dec 5, 2025

Study contacts

Zhe Chen, MD, PhD
Contact
chenzhe@yamanashi.ac.jp
+81-55-273-1111
Hiroshi Onishi, MD, PhD
Contact
honishi@yamanashi.ac.jp
+81-55-273-1111
Hiroshi Onishi, MD, PhD
principal investigator · University of Yamanashi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion